References
- Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet’s disease: a comprehensive review. J Autoimmun. 2015;64:137–48. doi:https://doi.org/10.1016/j.jaut.2015.08.013.
- Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Sadeghi Abdollahi B, Ashofteh F, et al. 2017. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 13(1):57–65. doi:https://doi.org/10.1080/1744666X.2016.1205486
- Cho SB, Cho S, Bang D. 2012. New insights in the clinical understanding of Behçet’s disease. Yonsei Med J. 53(1):35–42. doi:https://doi.org/10.3349/ymj.2012.53.1.35
- Kirino Y, Nakajima H. 2019. Clinical and genetic aspects of Behçet’s disease in Japan. Int Med (Tokyo, Japan). 58(9):1199–207. doi:https://doi.org/10.2169/internalmedicine.2035-18
- Kanneganti TD, Lamkanfi M, Núñez G. 2007. Intracellular NOD-like receptors in host defense and disease. Immunity. 27(4):549‐559. doi:https://doi.org/10.1016/j.immuni.2007.10.002
- Takeuchi O, Akira S. 2010. Pattern recognition receptors and inflammation. Cell. 140(6):805–20. doi:https://doi.org/10.1016/j.cell.2010.01.022
- Strober W, Murray PJ, Kitani A, Watanabe T. 2006. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 6(1):9–20. doi:https://doi.org/10.1038/nri1747
- Inohara C, McDonald C, Nuñez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem. 2005;74:355–83. doi:https://doi.org/10.1146/annurev.biochem.74.082803.133347.
- Inohara N, Nuñez G. 2003. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol. 3(5):371–82. doi:https://doi.org/10.1038/nri1086
- Lamkanfi M, Dixit VM. 2014. Mechanisms and functions of inflammasomes. Cell. 157(5):1013–22. doi:https://doi.org/10.1016/j.cell.2014.04.007
- Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–65. doi:https://doi.org/10.1146/annurev.immunol.021908.132715.
- Hysi P, Kabesch M, Moffatt MF, Schedel M, Carr D, Zhang Y, Boardman B, von Mutius E, Weiland SK, Leupold W, et al. 2005. NOD1 variation, immunoglobulin E and asthma. Hum Mol Genet. 14(7):935–41. doi:https://doi.org/10.1093/hmg/ddi087
- Van Limbergen J, Nimmo ER, Russell RK, Drummond HE, Smith L, Anderson NH, Davies G, Arnott ID, Wilson DC, Satsangi J. 2007. Investigation of NOD1/CARD4 variation in inflammatory bowel disease using a haplotype-tagging strategy. Hum Mol Genet. 16(18):2175–86. doi:https://doi.org/10.1093/hmg/ddm169
- Le HT, Harton JA. Pyrin- and CARD-only proteins as regulators of NLR functions. Front Immunol. 2013;4:275. doi:https://doi.org/10.3389/fimmu.2013.00275.
- Abraham C, Cho JH. 2006. Functional consequences of NOD2 (CARD15) mutations. Inflamm Bowel Dis. 12(7):641–50. doi:https://doi.org/10.1097/01.MIB.0000225332.83861.5f
- Ghandil P, Chelala C, Dubois-Laforgue D, Senée V, Caillat-Zucman S, Kockum I, Luthman H, Nerup J, Pociot F, Timsit J, et al. 2005. Crohn’s disease associated CARD15 (NOD2) variants are not involved in the susceptibility to type 1 diabetes. Mol Genet Metab. 86(3):379–83. doi:https://doi.org/10.1016/j.ymgme.2005.07.029
- Freire P, Cardoso R, Figueiredo P, Donato MM, Ferreira M, Mendes S, Ferreira AM, Vasconcelos H, Portela F, Sofia C. 2014. NOD2 gene mutations in ulcerative colitis: useless or misunderstood? Int J Colorectal Dis. 29(6):653–61. doi:https://doi.org/10.1007/s00384-014-1850-x
- McGovern DP, Hysi P, Ahmad T, Van Heel DA, Moffatt MF, Carey A, Cookson WO, Jewell DP. 2005. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet. 14(10):1245–50. doi:https://doi.org/10.1093/hmg/ddi135
- Tanabe T, Ishige I, Suzuki Y, Aita Y, Furukawa A, Ishige Y, Uchida K, Suzuki T, Takemura T, Ikushima S, et al. 2006. Sarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium acnes. Biochim Biophys Acta. 1762(9):794–801. doi:https://doi.org/10.1016/j.bbadis.2006.07.006
- Chua KH, Ng JG, Ng CC, Hilmi I, Goh KL, Kee BP. Association of NOD1, CXCL16, STAT6 and TLR4 gene polymorphisms with Malaysian patients with Crohn’s disease. PeerJ. 2016;4:e1843. doi:https://doi.org/10.7717/peerj.1843.
- Ozen SC, Dagli U, Kiliç MY, Törüner M, Celik Y, Ozkan M, Soykan I, Cetinkaya H, Ulker A, Ozden A, et al. 2006. NOD2/CARD15, NOD1/CARD4, and ICAM-1 gene polymorphisms in Turkish patients with inflammatory bowel disease. J Gastroenterol. 41(4):304–10. doi:https://doi.org/10.1007/s00535-005-1780-z
- Belhaj R, Kaabachi W, Khalfallah I, Hamdi B, Hamzaoui K, Hamzaoui A. 2019. Gene variants, mRNA and NOD1/2 protein levels in Tunisian childhood asthma. Lung. 197(3):377–85. doi:https://doi.org/10.1007/s00408-019-00209-4
- Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Núñez G, Inohara N. 2008. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J. 27(2):373–83. doi:https://doi.org/10.1038/sj.emboj.7601962
- Nishio H, Kanno S, Onoyama S, Ikeda K, Tanaka T, Kusuhara K, Fujimoto Y, Fukase K, Sueishi K, Hara T. 2011. Nod1 ligands induce site-specific vascular inflammation. Arterioscler Thromb Vasc Biol. 31(5):1093–99. doi:https://doi.org/10.1161/ATVBAHA.110.216325
- Zhang J, Defelice AF, Hanig JP, Colatsky T. 2010. Biomarkers of endothelial cell activation serve as potential surrogate markers for drug-induced vascular injury. Toxicol Pathol. 38(6):856–71. doi:https://doi.org/10.1177/0192623310378866
- Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE, Lee BL, Shiffin N, Advincula R, Malynn BA, et al. 2008. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity. 28(3):381–90. doi:https://doi.org/10.1016/j.immuni.2008.02.002
- Li HL, Zhuo ML, Wang D, Wang AB, Cai H, Sun LH, Yang Q, Huang Y, Wei YS, Liu PP, et al. 2007. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation. 115(14):1885–94. doi:https://doi.org/10.1161/CIRCULATIONAHA.106.656835
- Tiszlavicz Z, Somogyvári F, Kocsis AK, Szolnoki Z, Sztriha LK, Kis Z, Vécsei L, Mándi Y. 2009. Relevance of the genetic polymorphism of NOD1 in Chlamydia pneumoniae seropositive stroke patients. Eur J Neurol. 16(11):1224–29. doi:https://doi.org/10.1111/j.1468-1331.2009.02698.x
- Weidinger S, Klopp N, Rummler L, Wagenpfeil S, Novak N, Baurecht HJ, Groer W, Darsow U, Heinrich J, Gauger A, et al. 2005. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J Allergy Clin Immunol. 116(1):177–84. doi:https://doi.org/10.1016/j.jaci.2005.02.034
- Correa RG, Milutinovic S, Reed JC. 2012. Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases. Biosci Rep. 32(6):597–608. doi:https://doi.org/10.1042/BSR20120055
- Mayle S, Boyle JP, Sekine E, Zurek B, Kufer TA, Monie TP. 2014. Engagement of nucleotide-binding oligomerization domain-containing protein 1 (NOD1) by receptor-interacting protein 2 (RIP2) is insufficient for signal transduction. J Biol Chem. 289(33):22900–14. doi:https://doi.org/10.1074/jbc.M114.557900
- Li L, Yu H, Jiang Y, Deng B, Bai L, Kijlstra A, Yang P. Genetic variations of NLR family genes in Behcet’s disease. Sci Rep. 2016;6:20098. doi:https://doi.org/10.1038/srep20098.
- Huebner C, Ferguson LR, Han DY, Philpott M, Barclay ML, Gearry RB, McCulloch A, Demmers PS, Browning BL. Nucleotide-binding oligomerization domain containing 1 (NOD1) haplotypes and single nucleotide polymorphisms modify susceptibility to inflammatory bowel diseases in a New Zealand caucasian population: a case-control study. BMC Res Notes. 2009;2:52. doi:https://doi.org/10.1186/1756-0500-2-52.
- Park JH, Kim YG, McDonald C, Kanneganti TD, Hasegawa M, Body-Malapel M, Inohara N, Núñez G. 2007. RICK/RIP2 Mediates Innate Immune Responses Induced through Nod1 and Nod2 but Not TLRs. J Immunol (Baltimore, Md.: 1950). 178(4):2380–86. doi:https://doi.org/10.4049/jimmunol.178.4.2380
- Maharana J, Pradhan SK, De S. 2017. NOD1CARD might be using multiple interfaces for RIP2-Mediated CARD-CARD interaction: insights from molecular dynamics simulation. PloS One. 12(1):e0170232. doi:https://doi.org/10.1371/journal.pone.0170232
- Plantinga TS, Fransen J, Knevel R, Netea MG, Zwerina J, Helsen MM, van der Meer JW, Van Riel PL, Schett G, Van Der Helm-van Mil AH, et al. 2013. Role of NOD1 polymorphism in susceptibility and clinical progression of rheumatoid arthritis. Rheumatology (Oxford, England). 52(5):806–14. doi:https://doi.org/10.1093/rheumatology/kes404
- Joosten LA, Heinhuis B, Abdollahi-Roodsaz S, Ferwerda G, Lebourhis L, Philpott DJ, Nahori MA, Popa C, Morre SA, van der Meer JW, et al. 2008. Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. Proc Natl Acad Sci U S A. 105(26):9017–22. doi:https://doi.org/10.1073/pnas.0710445105
- Hamzaoui K, Abid H, Berraies A, Ammar J, Hamzaoui A. NOD2 is highly expressed in Behçet disease with pulmonary manifestations. J Inflamm (Lond). 2012 Feb 13;9(1):3. doi:https://doi.org/10.1186/1476-9255-9-3